Get started
Author

Deborah F. L. King

Observed names: D. F. L. King, D. King, Deborah F King, Deborah F. King, Deborah F. L King, Deborah F.L. King, Deborah King, King, D, King, Deborah
ORCID: 0000-0003-3199-5728
Observed ORCID: 0000-0003-3199-5728
OpenAlex ID: A5102881142
Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies
2016 · Hannah M. Cheeseman, Natalia J. Olejniczak, et al. · Journal of Virology · 37
Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions
2017 · Anush Arakelyan, Wendy Fitzgerald, et al. · Scientific Reports · 34
PDF
TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes
2016 · Paul F. McKay, Deborah F. L. King, et al. · PLoS ONE · 34
PDF
Aggregate complexes of HIV-1 induced by multimeric antibodies
2014 · Daniel J Stieh, Deborah F King, et al. · Retrovirology · 34
PDF
Mucosal Tissue Tropism and Dissemination of HIV-1 Subtype B Acute Envelope-Expressing Chimeric Virus
2012 · Deborah F. L. King, Asna A. Siddiqui, et al. · Journal of Virology · 29
Expression Profile of Human Fc Receptors in Mucosal Tissue: Implications for Antibody-Dependent Cellular Effector Functions Targeting HIV-1 Transmission
2016 · Hannah M. Cheeseman, Ann M. Carias, et al. · PLoS ONE · 28
PDF
Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses
2017 · Paul F. McKay, Jamie F.S. Mann, et al. · Journal of Controlled Release · 27
PDF
WFDC1/ps20 Is a Novel Innate Immunomodulatory Signature Protein of Human Immunodeficiency Virus (HIV)-Permissive CD4+CD45RO+Memory T Cells That Promotes Infection by Upregulating CD54 Integrin Expression and Is Elevated in HIV Type 1 Infection
2007 · R. Alvarez, J. Reading, et al. · Journal of Virology · 24
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013–2016 West Africa Ebola outbreak in Guinea
2020 · Yap Boum, Aitana Juan-Giner, et al. · Vaccine · 23
A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system
2018 · Joshua Pankrac, Katja Klein, et al. · npj Vaccines · 23
PDF
A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens
2017 · Sven Kratochvil, Paul F. McKay, et al. · Frontiers in Immunology · 21
PDF
Evaluation of mucosal adjuvants and immunization routes for the induction of systemic and mucosal humoral immune responses in macaques
2015 · Ronald S Veazey, Asna Siddiqui, et al. · Human Vaccines & Immunotherapeutics · 19
PDF
Discrete partitioning of HIV-1 Env forms revealed by viral capture
2015 · Daniel J. Stieh, Deborah F. King, et al. · Retrovirology · 18
PDF
A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection
2020 · Jamie F.S. Mann, Joshua Pankrac, et al. · EBioMedicine · 16
PDF
Evidence for Gag p24-specific CD4 T cells with reduced susceptibility to R5 HIV-1 infection in a UK cohort of HIV-exposed-seronegative subjects
2003 · Josiah Eyeson, Deborah King, et al. · AIDS · 16
Infection with multiple HIV-1 founder variants is associated with lower viral replicative capacity, faster CD4+ T cell decline and increased immune activation during acute infection
2020 · Gladys N. Macharia, Ling Yue, et al. · PLoS Pathogens · 15
PDF
Development of a sensitive, quantitative assay with broad subtype specificity for detection of total HIV-1 nucleic acids in plasma and PBMC
2022 · C. N. Kibirige, M. Manak, et al. · Scientific Reports · 14
PDF
Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein
2013 · Daniel J Stieh, Joshua L Phillips, et al. · Retrovirology · 14
PDF
Infection of stationary human brain aggregates with HIV‐1 SF162 and IIIB results in transient neuronal damage and neurotoxicity
2004 · G. Trillo‐Pazos, A. Kandanearatchi, et al. · Neuropathology and Applied Neurobiology · 13
Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa
2025 · Chama Chanda, Freddie Kibengo, et al. · The Lancet Microbe · 10
PDF
Mosaic HIV-1 vaccination induces anti-viral CD8 + T cell functionality in the phase 1/2a clinical trial APPROACH
2023 · Janine van Duijn, Daniel Stieh, et al. · Journal of Virology · 9
Breadth of CD8 T-cell mediated inhibition of replication of diverse HIV-1 transmitted-founder isolates correlates with the breadth of recognition within a comprehensive HIV-1 Gag, Nef, Env and Pol potential T-cell epitope (PTE) peptide set
2021 · Peter Hayes, Natalia Fernandez, et al. · PLoS ONE · 9
PDF
Plasmid DNA Vaccine Co-Immunisation Modulates Cellular and Humoral Immune Responses Induced by Intranasal Inoculation in Mice
2015 · Deborah F. L. King, Paul F. McKay, et al. · PLoS ONE · 9
PDF
Assessment of a diverse panel of transmitted/founder HIV-1 infectious molecular clones in a luciferase based CD8 T-cell mediated viral inhibition assay
2022 · Natalia Fernandez, Peter Hayes, et al. · Frontiers in Immunology · 6
PDF
A Novel Sample Selection Approach to Aid the Identification of Factors That Correlate With the Control of HIV-1 Infection
2021 · Julia Makinde, Eunice W. Nduati, et al. · Frontiers in Immunology · 4
PDF
Works count: 41
Citation count: 492
H-index: 15
I10-index: 20
Year
Topic
Type